Recent Publications
Lindberg J, Mills IG, Klevebring D, Liu W, Neiman M, Xu J, Wikstrom P, Wiklund P, Wiklund F, Egevad L, Gronberg H.
The mitochondrial and autosomal mutation landscapes of prostate cancer. Eur Urol. 2013;63(4):702-708.
Lu Y, Sun J, Kader AK, Kim S-T, Kim J-W, Liu W, Sun J, Lu D, Feng J, Zhu Y, Jin T, Zhang Z, Dimitrov L, Lowey J, Campbell K, Suh E, Duggan D, Carpten J, Trent JM, Gronberg H, Zheng SL, Isaacs WB, Xu J.
Association of prostate cancer risk with SNPs in regions containing androgen receptor binding sites captured by ChIP-On-chip analyses. Prostate. 2012;72(4):376-385.
Wu M, Shi L, Cimic A, Romero L, Sui G, Lees CJ, Cline JM, Seals DF, Sirintrapun JS, McCoy TP, Liu W, Kim JW, Hawkins GA, Peehl DM, Xu J, Cramer SD.
Suppression of Tak1 promotes prostate tumorigenesis. Cancer Res. 2012;72(11):2833-2843.
Liu W, Lindberg J, Sui G, Luo J, Egevad L, Li T, Xie C, Wan M, Kim S-T, Wang Z, Turner AR, Zhang Z, Feng J, Yan Y, Sun J, Bova GS, Ewing CM, Yan G, Gielzak M, Cramer SD, Vessella RL, Zheng SL, Gronberg H, Isaacs WB, Xu J.
Identification of novel CHD1-associated collaborative alterations of genomic structure and functional assessment of CHD1 in prostate cancer. Oncogene. 2012;31(35):3939-3948.
Hager MH, Morley S, Bielenberg DR, Gao S, Morello M, Holcomb IN, Liu W, Mouneimne G, Demichelis F, Kim J, Solomon KR, Adam RM, Isaacs WB, Higgs HN, Vessella RL, Di Vizio D, Freeman MR.
DIAPH3 governs the cellular transition to the amoeboid tumour phenotype. EMBO Mol Med. 2012;4(8):743-760.
Kim JW, Kim ST, Turner AR, Young T, Smith S, Liu W, Lindberg J, Egevad L, Gronberg H, Isaacs WB, Xu J.
Identification of new differentially methylated genes that have potential functional consequences in prostate cancer. PLoS One. 2012;7(10):e48455.
Xu J, Mo Z, Ye D, Wang M, Liu F, Jin G, Xu C, Wang X, Shao Q, Chen Z, Tao Z, Qi J, Zhou F, Wang Z, Fu Y, He D, Wei Q, Guo J, Wu D, Gao X, Yuan J, Wang G, Xu Y, Wang G, Yao H, Dong P, Jiao Y, Shen M, Yang J,.
Genome-wide association study in Chinese men identifies two new prostate cancer risk loci at 9q31.2 and 19q13.4. Nat Genet. 2012;44(11):1231-1235.
Jin G, Sun J, Liu W, Zhang Z, Chu LW, Kim S-T, Sun J, Feng J, Zheng SL, Xu J, et al.
Genome-wide copy-number variation analysis identifies common genetic variants at 20p13 associated with aggressiveness of prostate cancer. Carcinogenesis. 2011;32(7):1057-1062.
Lotan TL, Gurel B, Sutcliffe S, Esopi D, Liu W, Xu J, Hicks JL, Park BH, Humphreys E, Partin AW, Han M, Netto GJ, Isaacs WB, De Marzo AM.
PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin Cancer Res. 2011;17(20):6563-6573.
Haffner MC, Aryee MJ, Toubaji A, Esopi DM, Albadine R, Gurel B, Isaacs WB, Bova GS, Liu W, Xu J, et al.
Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet. 2010;42(8):668-675.
Cheng Y, Kim JW, Liu W, Dunn TA, Luo J, Loza MJ, Kim S-T, Zheng SL, Xu J, Chang B-L, et al.
Genetic and epigenetic inactivation of TNFRSF10C in human prostate cancer. Prostate. 2009;69(3):327-335.
Sun J, Zheng SL, Li G, Kim S-T, Zhu Y, Zhang Z, Hsu F-C, Turner AR, Liu W, Kim JW, Xu J, Chang B-L, et al.
Sequence variants at 22q13 are associated with prostate cancer risk. Cancer Res. 2009;69(1):10-15.
Zheng SL, Sun J, Gao Z, Purcell LD, Hsu F-C, Zhu Y, Turner AR, Adams TS, Liu W, Chang B-L, Xu J, et al.
Genetic variants and family history predict prostate cancer similar to prostate-specific antigen. Clin Cancer Res. 2009;15(3):1105-1111.
Liu W, Sun J, Li G, Zhu Y, Zhang S, Kim S-T, Sun J, Xu J, Zheng SL, Chang B-L, et al.
Association of a germ-line copy number variation at 2p24.3 and risk for aggressive prostate cancer. Cancer Res. 2009;69(6):2176-2179.
Chang B-L, Cramer SD, Sun J, Smith S, Pruett K, Romero LM, Zhu Y, Zhang Z, Hsu F-C, Turner AR, Liu W, Kim JW, Zheng SL, Xu J, et al.
Fine mapping association study and functional analysis implicate a SNP in MSMB at 10q11 as a causal variant for prostate cancer risk. Hum Mol Genet. 2009;18(7):1368-1375.
Hsu F-C, Sun J, Purcell LD, Gao Z, Zhu Y, Kim S-T, Zhang Z, Liu W, Chang B-L, Xu J, Zheng SL, et al.
A novel prostate cancer susceptibility locus at 19q13. Cancer Res. 2009;69(7):2720-2723.
Liu W, Laitinen S, Khan S, Vihinen M, Kowalski J, Yu G, Chen L, Ewing CM, Eisenberger MA, Xu J, et al.
Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer [research letter]. Nat Med. 2009;15(5):559-565.
Zheng SL, Sun J, Smith S, Pruett K, Kim S-T, Zhu Y, Zhang Z, Hsu F-C, Turner AR, Liu W, Kim JW, Chang B-L, Xu J, et al.
Two independent prostate cancer risk-associated Loci at 11q13. Cancer Epidemiol Biomarkers Prev. 2009;18(6):1815-1820.
Sun J, Lange EM, Isaacs SD, Liu W, Wiley KE, Lange L, Gronberg H, Xu J, Chang B-L, Zheng SL, et al.
Chromosome 8q24 risk variants in hereditary and non-hereditary prostate cancer patients. Prostate. 2008;68(5):489-497.
Zheng SL, Sun J, Smith S, Li G, Hsu F-C, Zhu Y, Kader AK, Turner AR, Liu W, Bleecker ER, Meyers DA, Chang B-L, Xu J, et al.
Cumulative association of five genetic variants with prostate cancer. N Engl J Med. 2008;358(9):910-919.
Sun J, Purcell L, Gao Z, Isaacs SD, Wiley KE, Hsu F-C, Liu W, Xu J, Chang B-L, Zheng SL, et al.
Association between sequence variants at 17q12 and 17q24.3 and prostate cancer risk in European and African Americans. Prostate. 2008;68(7):691-697.
Hsu F-C, Lindstrom S, Sun J, Wiklund F, Turner AR, Liu W, Kim JW, Chang B-l, Xu J, Zheng SL, et al.
A multigenic approach to evaluating prostate cancer risk in a systematic replication study. Cancer Genet Cytogenet. 2008;183(2):94-98.
Kader AK, Sun J, Yang G, Zheng L, Xu J, Liu W, Issacs WB. Loss of chromosome 17p13.1 significantly correlates with Gleason score at the time of radical prostatectomy [abstract]. J Urol. 2008;179(4 Suppl):227-228.
Sun J, Zheng SL, Purcell LD, Gao Z, Hsu F-C, Kim S-T, Liu W, Zhu Y, Dimitrov L, Sun J, Li T, Turner AR, Adams TS, Chang B-L, Xu J, et al.
Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12. Nat Genet. 2008;40(10):1153-1155.
Xu J, Sun J, Li G, Zhu Y, Hsu F-C, Turner AR, Adams TS, Liu W, Chang B, Zheng S, et al.
Association of prostate cancer risk variants with clinicopathologic characteristics of the disease. Clin Cancer Res. 2008;14(18):5819-5824.
Liu W, Xie CC, Zhu Y, Li T, Sun J, Cheng Y, Turner AR, Sun J, Chang B-L, Zheng SL, Xu J, et al.
Homozygous deletions and recurrent amplifications implicate new genes involved in prostate cancer. Neoplasia. 2008;10(8):897-907.
Liu W, Chang B, Li T, Dimitrov L, Kim S, Kim JW, Turner AR, Meyers DA, Zheng SL, Xu J, et al.
Germline copy number polymorphisms involving larger than 100 kb are uncommon in normal subjects. Prostate. 2007;67(3):227-233.
Sun J, Liu W, Adams TS, Sun J, Li X, Turner AR, Chang B, Kim JW, Zheng SL, Xu J, et al.
DNA copy number alterations in prostate cancers: a combined analysis of published CGH studies. Prostate. 2007;67(7):692-700.
Daunais JB, Liu W, Wyatt CL, Szeliga KT, Buchheimer NC, Gage HD, Kraft RA, Friedman DP. Ethanol-induced volume changes in Macaque brain [abstract]. Alcohol Clin Exp Res. 2007;31(6 Suppl):147A.
Liu W, Chang B-L, Li T, Sun J, Turner AR, Dimitrov L, Zhu Y, Sun J, Kim JW, Zheng SL, Xu J, et al.
Multiple genomic alterations on 21q22 predict various TMPRSS2/ERG fusion transcripts in human prostate cancers. Genes Chromosomes Cancer. 2007;46(11):972-980.
Liu W, Chang B-L, Cramer S, Koty PP, Li T, Sun J, Turner AR, Von Hap-Herr C, Zheng SL, Xu J, et al.
Deletion of a small consensus region at 6q15, including the MAP3K7 gene, is significantly associated with high-grade prostate cancers. Clin Cancer Res. 2007;13(17):5028-5033.
Zheng SL, Sun J, Cheng Y, Li G, Hsu F-C, Zhu Y, Chang B-L, Liu W, Kim JW, Turner AR, Xu J, et al.
Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans. J Natl Cancer Inst. 2007;99(20):1525-1533.
Duggan D, Zheng SL, Dimitrov L, Cheng Y, Li G, Sun J, Chang B-L, Liu W, Kim JW, Bleecker ER, Meyers DA, Xu J, et al.
Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB21P. J Natl Cancer Inst. 2007;99(24):1836-1844.
Xu J, Sauvageot J, Ewing CM, Sun J, Liu W, Isaacs SD, Wiley KE, Diaz L, Zheng SL, Walsh PC, et al.
Germline ATBF1 mutations and prostate cancer risk. Prostate. 2006;66(10):1082-1085.
Shahedi K, Lindstrom S, Zheng SL, Wiklund F, Adolfsson J, Sun J, Augustsson-Balter K, Chang B-L, Liu W, Xu J, et al.
Genetic variation in the COX-2 gene and the association with prostate cancer risk. Int J Cancer. 2006;119(3):668-672.
Liu W, Chang B, Sauvageot J, Dimitrov L, Gielzak M, Li T, Yan G, Sun J, Sun J, Adams TS, Turner AR, Kim JW, Meyers DA, Zheng SL, Isaacs WB, Xu J.
Comprehensive assessment of DNA copy number alterations in human prostate cancers using Affymetrix 100K SNP mapping array. Genes Chromosomes Cancer. 2006;45(11):1018-1032.
Zheng SL, Liu W, Dimitrov L, Sun J, Sun J, Chang B, Loza M, Turner AR, Bleecker ER, Meyers DA, Xu J, et al.
A comprehensive association study for genes in inflammation pathway provides support for their roles in prostate cancer risk in the CAPS Study. Prostate. 2006;66(14):1556-1564.
Lindstrom S, Zheng SL, Wiklund F, Jonsson B-A, Adami H-O, Balter KA, Brookes AJ, Sun J, Chang B-L, Liu W, Li G, Xu J, et al.
Systematic replication study of reported genetic associations in prostate cancer: strong support for genetic variation in the androgen pathway. Prostate. 2006;66(16):1729-1743.
All Publications
For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.
For a list of earlier publications, visit the Carpenter Library Publication Search.